A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Trial Profile

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Erlotinib (Primary) ; Sirolimus (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.
    • 22 Sep 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov record
    • 01 Jun 2014 The trial design and progress status presented at 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top